

Supplemental Table S1. Unadjusted Risk of Major Osteoporotic and Hip Fractures by Medication(s) Used

Group	Major osteoporotic fracture			Hip fracture		
	HR	95% CI	<i>P</i> value	HR	95% CI	<i>P</i> value
Non-user (<i>n</i> =2,868)	Ref			Ref		
User (<i>n</i> =3,305)	1.16	0.98–1.37	0.079	1.07	0.76–1.50	0.687
Non-user (<i>n</i> =2,868)	Ref			Ref		
LTA (<i>n</i> =2,281)	1.02	0.84–1.23	0.817	0.87	0.58–1.28	0.487
ICS (<i>n</i> =517)	1.43	1.08–1.91	0.012	1.45	0.82–2.56	0.190
ICS+LABA (<i>n</i> =507)	1.55	1.17–2.05	0.002	1.62	0.94–2.78	0.077
LTA (<i>n</i> =2,281)	Ref			Ref		
ICS (<i>n</i> =517)	1.53	1.15–2.05	0.003	1.71	0.94–3.09	0.073
ICS+LABA (<i>n</i> =507)	1.41	1.05–1.90	0.019	1.88	1.07–3.31	0.027

Univariate Cox regression analyses were performed.

HR, hazard ratio; CI, confidence interval; LTA, leukotriene antagonist; ICS, inhaled corticosteroid; LABA, long-acting beta-agonist.